PGY-2 Medication-Use Safety & Policy Resident Dana-Farber Cancer Institute Brighton, Massachusetts, United States
Poster Abstract: Background/Rationale: Sacituzumab govitecan is a Trop-2 directed antibody drug conjugate used in the management of advanced breast and urothelial cancers. The recommended infusion schedule per the package insert is to administer the first infusion over three hours and subsequent infusions over one to two hours. The purpose of this study is to determine if there is a difference in adverse reaction rates between one hour or two-hour infusion times.
Objective(s): The primary objective is to evaluate the rate and grade of hypersensitivity reactions and acute cholinergic reactions when sacituzumab govitecan is administered over one or two hours. Secondary objectives include the rates of neutropenia, febrile neutropenia, use of granulocyte-colony stimulating factors, or changes in premedications due to a previous reaction.
Methods: This is a retrospective chart review of patients at Dana-Farber Cancer Institute who received sacituzumab govitecan between January 2022 to July 2023. Patients are identified via a sacituzumab govitecan electronic medical record administration report. Eligible patients received their first infusion over three hours and received at least one subsequent infusion between one to two hours. Investigational sacituzumab govitecan infusions are excluded. Patients are grouped into a one hour or two-hour arm based on their documented administration times. Data will be collected from progress notes, home medication lists, medication administration records, and laboratory reports. A maximum of four infusions will be assessed. Endpoints will be evaluated with descriptive statistics.
